健康な青年における異なる投与スケジュールで投与された男性ABCWYの安全性、忍容性、および免疫原性
健康な青年に異なる投与スケジュールで投与された男性ABCWYの安全性、忍容性、および免疫原性を説明する第IIb相無作為化観察者盲検試験
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35205
- GSK Investigational Site
-
-
Arizona
-
Tucson、Arizona、アメリカ、85745-2696
- GSK Investigational Site
-
-
California
-
Ventura、California、アメリカ、93003
- GSK Investigational Site
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20016
- GSK Investigational Site
-
-
Florida
-
Miami、Florida、アメリカ、33173
- GSK Investigational Site
-
Miami、Florida、アメリカ、33156-7397
- GSK Investigational Site
-
-
Georgia
-
Macon、Georgia、アメリカ、31210
- GSK Investigational Site
-
-
Indiana
-
Valparaiso、Indiana、アメリカ、84088
- GSK Investigational Site
-
-
Kentucky
-
Nicholasville、Kentucky、アメリカ、40517
- GSK Investigational Site
-
-
Louisiana
-
Haughton、Louisiana、アメリカ、71037
- GSK Investigational Site
-
-
Montana
-
Missoula、Montana、アメリカ、59804
- GSK Investigational Site
-
Missoula、Montana、アメリカ、80216
- GSK Investigational Site
-
-
Nebraska
-
Grand Island、Nebraska、アメリカ、68803
- GSK Investigational Site
-
Lincoln、Nebraska、アメリカ、68510
- GSK Investigational Site
-
Omaha、Nebraska、アメリカ、68134
- GSK Investigational Site
-
-
New York
-
Binghamton、New York、アメリカ、13905-1118
- GSK Investigational Site
-
Endwell、New York、アメリカ、13850
- GSK Investigational Site
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28226
- GSK Investigational Site
-
-
Oregon
-
Gresham、Oregon、アメリカ、97030
- GSK Investigational Site
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29414-5834
- GSK Investigational Site
-
-
Tennessee
-
Kingsport、Tennessee、アメリカ、37660
- GSK Investigational Site
-
-
Texas
-
Austin、Texas、アメリカ、75024
- GSK Investigational Site
-
Galveston、Texas、アメリカ、77555 1115
- GSK Investigational Site
-
-
Utah
-
Layton、Utah、アメリカ、84037
- GSK Investigational Site
-
-
-
-
-
Bramsche、ドイツ、49565
- GSK Investigational Site
-
Herxheim、ドイツ、76863
- GSK Investigational Site
-
Leipzig、ドイツ、16269
- GSK Investigational Site
-
Mannheim、ドイツ、68309
- GSK Investigational Site
-
Schweigen-Rechtenbach、ドイツ、76889
- GSK Investigational Site
-
-
Bavaria
-
Schönau、Bavaria、ドイツ、83471
- GSK Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
-
Written or witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
-
Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure.
-
A male or female between, and including, 11 and 14 years of age (i.e. 14 years + 364 days) at the time of the first vaccination.
-
Healthy participants as established by medical history, physical examination and clinical judgment of the investigator before entering into the study.
-
Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral-salpingectomy or bilateral ovariectomy.
-
Female participants of childbearing potential may be enrolled in the study, if the participant:
- has practiced adequate contraception for 30 days prior to first vaccination, and
- has a negative pregnancy test* on the day of vaccination, and
- has agreed to follow adequate contraception for 30 days before each of the 2 subsequent vaccinations and for 30 days after each vaccination * Urine samples for pregnancy testing will be collected from female participants of childbearing potential at Visit 1, Visit 3 and Visit 5 prior to the vaccination.
Exclusion Criteria:
Medical conditions
-
Current or previous, confirmed or suspected disease caused by N. meningitidis.
-
Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.
-
Progressive, unstable or uncontrolled clinical conditions.
-
Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
-
Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion.
-
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s)/product(s).
- Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study.
-
Abnormal function or modification of the immune system resulting from:
- Autoimmune disorders or immunodeficiency syndromes.
- Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.
- Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
- Administration of long-acting immune-modifying drugs at any time during the study period.
-
Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
Prior/Concomitant therapy
- Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period.
- Previous vaccination with any meningococcal (MenB or MenACWY) vaccine at any time prior to informed consent/ assent (as applicable) with the exception of meningococcal C (conjugated or polysaccharide) vaccination, if the last dose of MenC was received at ≤24 months of age.
- Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of study vaccine/product or planned administration before the next blood sampling visit.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/product dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.
Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device).
Other exclusions
- Child in care.
- Pregnant or lactating female.
- Female planning to become pregnant / planning to discontinue contraceptive precautions during the windows reported in the inclusion criterion.
- History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator.
- Any study personnel or immediate dependants, family, or household members.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ABCWY-24 Group
Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441. |
Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group. Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group. |
|
実験的:ABCWY-48 Group
Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721. |
Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group. Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with human serum bactericidal assay (hSBA) titers ≥ lower limit of quantitation (LLOQ) for each N. meningitidis serogroup B indicator strains
時間枠:At Baseline (Day 1)
|
The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains. |
At Baseline (Day 1)
|
|
Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains
時間枠:At 1 month after the second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
|
The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains. |
At 1 month after the second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
|
|
Percentage of participants with solicited administration site events
時間枠:During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
The solicited administration site events include pain, redness, swelling and induration. Redness, swelling, and induration are summarized according to defined severity grading scales: None (0 to 24mm); Mild (25 to 50mm); Moderate (51 to 100mm); Severe (>100mm). Injection site pain is summarized according to "mild", "moderate" or "severe". |
During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
|
Percentage of participants with solicited systemic events
時間枠:During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
The solicited systemic events include fever, headache, nausea, myalgia, arthralgia and fatigue. Fever is defined as body temperature 38.0°C (100.4°F). The preferred location for measuring temperature in this study is the oral route. Solicited systemic events (except fever) are summarized according to "mild", "moderate" or "severe". |
During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
|
Percentage of participants with any unsolicited adverse events (AEs) including all serious adverse events (SAEs), AEs leading to withdrawal, adverse events of special interest (AESIs) and medically attended AEs
時間枠:During the 30 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
An unsolicited AE is an AE that was not included in a list of solicited events and must have been spontaneously communicated by a participant/participant's parent(s)/ Legally Acceptable Representative(s) who has signed the informed consent. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider. |
During the 30 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)
|
|
Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs
時間枠:During the 6 months (including the day of vaccination) following the first vaccination (Vaccine administered at Day 1)
|
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider. |
During the 6 months (including the day of vaccination) following the first vaccination (Vaccine administered at Day 1)
|
|
Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs
時間枠:During the 6 months (including the day of vaccination) following the second vaccination (Vaccine administered at Day 721)
|
An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider. |
During the 6 months (including the day of vaccination) following the second vaccination (Vaccine administered at Day 721)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of participants with hSBA titers ≥ LLOQ for N. meningitidis serogroups A, C, W and Y
時間枠:At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
|
The immune response to 1 and 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against N. meningitidis serogroups A, C, W and Y. |
At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)
|
|
Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains and for serogroups A, C, W and Y
時間枠:At 25 months after the second dose of MenABCWY (Day 1471 for the ABCWY-24 Group)
|
The antibody persistence at 25 months after the second dose of the MenABCWY vaccine administered on a 0-, 24-month schedule is evaluated against each N. meningitidis serogroup B indicator strains and serogroups A, C, W and Y. |
At 25 months after the second dose of MenABCWY (Day 1471 for the ABCWY-24 Group)
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 215344
- 2021-001670-33 (EudraCT番号)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
IPD for this study will be made available via the Clinical Study Data Request site.
IPD 共有時間枠
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD 共有アクセス基準
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。